Viewing Study NCT06708858


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2025-12-25 @ 9:59 PM
Study NCT ID: NCT06708858
Status: RECRUITING
Last Update Posted: 2024-11-27
First Post: 2024-11-11
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Sponsor: Dai, Guanghai
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module